Plain-English translation of NCT07204574 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called combined with standard chemotherapy and two other targeted cancer drugs ( and cetuximab) for people with advanced colorectal cancer that has spread to other parts of the body or cannot be removed with surgery. The study wants to find the right dose of the medication, understand how safe it is, and see whether it helps people live longer and feel better.
Advanced colorectal cancer is hard to treat, and many patients do not respond well enough to current standard treatments alone. This medication is designed to work with your immune system in a new way, and researchers believe combining it with existing chemotherapy drugs might give patients a better chance of fighting their cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication through an IV infusion once a week (on days 1, 8, and 15 of each 21-day cycle), along with chemotherapy and other targeted drugs given every two weeks. You will continue this treatment until your cancer stops responding, you experience unacceptable side effects, or you choose to withdraw. You will have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and track any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Taiwan